Division of Rheumatology, Beth Israel Medical Center, New York, NY 10003, USA.
Clin Interv Aging. 2009;4:207-14. doi: 10.2147/cia.s4080. Epub 2009 May 14.
Fragility fractures that occur as a result of osteoporosis are frequently associated with chronic pain and decreased quality of life as well as significant morbidity and mortality. Fracture reduction, however, is often less than optimal due to poor compliance with medications. Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, dosing options, and tolerability of risedronate are reviewed.
由于骨质疏松症而发生的脆性骨折常伴有慢性疼痛和生活质量下降，以及显著的发病率和死亡率。然而，由于药物依从性差，骨折的减少往往不理想。研究表明，含有杂环氮的双膦酸盐利塞膦酸钠可降低绝经后妇女、男性以及跌倒和脆性骨折风险较高的老年患者亚组的椎体、非椎体和髋部骨折的发生率。本文综述了利塞膦酸钠的作用机制、疗效、剂量选择和耐受性。
